Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Independence of Lipoprotein(a) and Low-Density Lipoprotein Cholesterol–Mediated Cardiovascular Risk: A Participant-Level Meta-Analysis

Circulation(2024)10.1161/circulationaha.124.069556Source: DataRank Database

Independence of Lipoprotein(a) and Low-Density Lipoprotein Cholesterol–Mediated Cardiovascular Risk: A Participant-Level Meta-Analysis is a research paper published in Circulation (2024). On theSindex it has a DataRank of 0. It has been cited 88 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access88 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 39.61)OA: hybridTopics (55)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (13)

Simon Wandel,Peter Willeit ORCID,Anastasia Lesogor,Keith Bailey ORCID,Paul M. Ridker ORCID

Live enrichment

PubMed:39492722 PMC:PMC11771346 OpenAlex:https://openalex.org/W4404019593

NHLBI NIH HHS

Grant: K08 HL166962

National Institutes of Health

Grant: 1K08HL166962-01A1

Aspirin for Primary Prevention of Cardiovascular Disease in Patients with Elevated Lipoprotein(a)

National Institutes of Health

Grant: 5KL2TR001444-03

UC San Diego Clinical and Translational Research Institute

National Institutes of Health

Grant: 1R01HL170224-01

Aspirin, Lp(a) and Primary Prevention of Cardiovascular Events

National Institutes of Health

Grant: 5R01HL159156-02

Translating Lp(a) biology to clinical applications

FWCI

39.61

Citation Percentile

1.0%

Citation Trend

2025

2026

hybridLicense: cc-by

journalhttps://doi.org/10.1161/circulationaha.124.069556

publisherhttps://doi.org/10.1161/circulationaha.124.069556

publisherhttps://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.124.069556

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39492722

repositoryhttps://escholarship.org/uc/item/44n5z1jm

Fields of Study

Lipoproteins and Cardiovascular HealthAtherosclerosis and Cardiovascular DiseasesPeripheral Artery Disease Management03 medical and health sciences0302 clinical medicine

MeSH Terms

Heart Disease Risk FactorsAgedCardiovascular DiseasesFemaleHumansCholesterol, LDLMaleMiddle AgedRisk FactorsProportional Hazards ModelsRandomized Controlled Trials as TopicLipoprotein(a)Hydroxymethylglutaryl-CoA Reductase Inhibitors

Keywords

MedicineInternal medicineQuartileAtherosclerotic cardiovascular diseaseHazard ratioStatinRosuvastatinProportional hazards modelLipoprotein(a)CardiologyLipoproteinPlaceboCholesterolEndocrinologyConfidence intervalDiseaseLipoproteins, LDLHeart Disease Risk FactorsMaleHydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use610Cardiovascular Diseases/bloodLipoprotein(a)/bloodLDLRisk FactorsOriginal Research ArticlesHumansProportional Hazards ModelsRandomized Controlled Trials as TopicAgedCholesterol, LDLMiddle AgedlipoproteinsCholesterol, LDL/bloodCardiovascular DiseasesFemaleHydroxymethylglutaryl-CoA Reductase Inhibitors

Sustainable Development Goals

SDG 0: Good health and well-being